Abatacept is a selective T cell co-stimulation modulator that was first approved by the Italian Medicines Agency and reimbursed by the Italian National Health Service when used to treat active rheumatoid arthritis "not sufficiently responsive to other disease-modifying anti-rheumatic drugs (DMARDs) including at least one TNF inhibitor", and is now also approved as a first line biological agent. The aim of this review is to summarise the safety data collected in clinical trials and observational studies.
Long-term safety of abatacept in patients with rheumatoid arthritis / F. Atzeni, P. Sarzi-Puttini, A. Mutti, S. Bugatti, L. Cavagna, R. Caporali. - In: AUTOIMMUNITY REVIEWS. - ISSN 1568-9972. - 12:12(2013 Dec), pp. 1115-1117.
|Titolo:||Long-term safety of abatacept in patients with rheumatoid arthritis|
|Parole Chiave:||Abatacept; Rheumatoid arthritis; Safety|
|Settore Scientifico Disciplinare:||Settore MED/16 - Reumatologia|
|Data di pubblicazione:||dic-2013|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1016/j.autrev.2013.06.011|
|Appare nelle tipologie:||01 - Articolo su periodico|